Cyclo Income Before Tax vs Selling And Marketing Expenses Analysis

CYTH Stock  USD 0.60  0.02  3.23%   
Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Income Before Tax and its Selling And Marketing Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Income Before Tax vs Selling And Marketing Expenses

Income Before Tax vs Selling And Marketing Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Income Before Tax account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have no relationship.
The correlation between Cyclo Therapeutics' Income Before Tax and Selling And Marketing Expenses is 0.06. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Income Before Tax and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Cyclo Therapeutics are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Income Before Tax i.e., Cyclo Therapeutics' Income Before Tax and Selling And Marketing Expenses go up and down completely randomly.

Correlation Coefficient

0.06
Relationship DirectionPositive 
Relationship StrengthInsignificant

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Cyclo Therapeutics income statement and is an important metric when analyzing Cyclo Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Selling And Marketing Expenses

Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Issuance Of Capital Stock is increasing as compared to previous years. The Cyclo Therapeutics' current Sales General And Administrative To Revenue is estimated to increase to 5.52, while Selling General Administrative is projected to decrease to under 2.9 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses15.7M16.8M17.6M18.5M
Cost Of Revenue156.1K138.9K3.5M3.7M

Cyclo Therapeutics fundamental ratios Correlations

0.150.740.85-0.22-0.96-0.710.810.98-0.28-0.350.980.680.64-0.23-0.160.530.790.730.990.4-0.28-0.420.49-0.3-0.52
0.150.41-0.150.610.11-0.390.14-0.030.570.31-0.03-0.320.580.41-0.140.450.370.470.040.76-0.21-0.37-0.54-0.230.3
0.740.410.29-0.27-0.64-0.950.940.68-0.34-0.480.680.250.94-0.07-0.20.740.950.990.750.79-0.23-0.180.33-0.27-0.6
0.85-0.150.29-0.15-0.89-0.30.450.88-0.19-0.190.880.790.18-0.26-0.040.20.40.280.84-0.04-0.23-0.430.5-0.23-0.33
-0.220.61-0.27-0.150.420.39-0.49-0.350.990.73-0.35-0.35-0.170.030.12-0.35-0.38-0.22-0.360.05-0.12-0.09-0.68-0.120.85
-0.960.11-0.64-0.890.420.63-0.79-0.990.470.46-0.99-0.74-0.50.280.16-0.45-0.71-0.62-0.98-0.220.20.37-0.650.220.63
-0.71-0.39-0.95-0.30.390.63-0.91-0.660.460.56-0.66-0.3-0.95-0.170.23-0.9-0.99-0.94-0.74-0.820.240.29-0.350.280.7
0.810.140.940.45-0.49-0.79-0.910.8-0.55-0.60.80.440.81-0.13-0.260.70.930.930.850.58-0.24-0.130.59-0.27-0.76
0.98-0.030.680.88-0.35-0.99-0.660.8-0.4-0.421.00.710.55-0.29-0.170.460.740.670.990.28-0.22-0.390.6-0.23-0.58
-0.280.57-0.34-0.190.990.470.46-0.55-0.40.8-0.4-0.36-0.240.030.12-0.41-0.45-0.28-0.42-0.03-0.15-0.04-0.68-0.140.86
-0.350.31-0.48-0.190.730.460.56-0.6-0.420.8-0.42-0.25-0.4-0.010.02-0.49-0.55-0.42-0.46-0.28-0.190.03-0.56-0.170.7
0.98-0.030.680.88-0.35-0.99-0.660.81.0-0.4-0.420.710.55-0.29-0.170.460.740.670.990.28-0.22-0.390.6-0.23-0.58
0.68-0.320.250.79-0.35-0.74-0.30.440.71-0.36-0.250.710.18-0.25-0.070.220.370.230.7-0.14-0.25-0.070.57-0.25-0.46
0.640.580.940.18-0.17-0.5-0.950.810.55-0.24-0.40.550.180.1-0.210.810.940.950.640.9-0.18-0.30.1-0.22-0.49
-0.230.41-0.07-0.260.030.28-0.17-0.13-0.290.03-0.01-0.29-0.250.1-0.190.560.11-0.06-0.220.34-0.06-0.35-0.23-0.050.0
-0.16-0.14-0.2-0.040.120.160.23-0.26-0.170.120.02-0.17-0.07-0.21-0.19-0.26-0.22-0.27-0.17-0.02-0.430.49-0.08-0.42-0.02
0.530.450.740.2-0.35-0.45-0.90.70.46-0.41-0.490.460.220.810.56-0.260.870.730.560.8-0.18-0.410.2-0.2-0.6
0.790.370.950.4-0.38-0.71-0.990.930.74-0.45-0.550.740.370.940.11-0.220.870.940.810.79-0.25-0.330.37-0.28-0.7
0.730.470.990.28-0.22-0.62-0.940.930.67-0.28-0.420.670.230.95-0.06-0.270.730.940.730.79-0.23-0.210.29-0.28-0.55
0.990.040.750.84-0.36-0.98-0.740.850.99-0.42-0.460.990.70.64-0.22-0.170.560.810.730.38-0.24-0.390.58-0.26-0.63
0.40.760.79-0.040.05-0.22-0.820.580.28-0.03-0.280.28-0.140.90.34-0.020.80.790.790.38-0.18-0.29-0.16-0.22-0.28
-0.28-0.21-0.23-0.23-0.120.20.24-0.24-0.22-0.15-0.19-0.22-0.25-0.18-0.06-0.43-0.18-0.25-0.23-0.24-0.18-0.33-0.240.990.34
-0.42-0.37-0.18-0.43-0.090.370.29-0.13-0.39-0.040.03-0.39-0.07-0.3-0.350.49-0.41-0.33-0.21-0.39-0.29-0.330.17-0.31-0.08
0.49-0.540.330.5-0.68-0.65-0.350.590.6-0.68-0.560.60.570.1-0.23-0.080.20.370.290.58-0.16-0.240.17-0.24-0.73
-0.3-0.23-0.27-0.23-0.120.220.28-0.27-0.23-0.14-0.17-0.23-0.25-0.22-0.05-0.42-0.2-0.28-0.28-0.26-0.220.99-0.31-0.240.35
-0.520.3-0.6-0.330.850.630.7-0.76-0.580.860.7-0.58-0.46-0.490.0-0.02-0.6-0.7-0.55-0.63-0.280.34-0.08-0.730.35
Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets4.1M14.2M19.5M4.2M13.2M13.9M
Total Current Liabilities3.1M3.7M3.8M3.5M8.5M8.9M
Total Stockholder Equity936.0K10.5M15.7M734.5K4.8M2.6M
Property Plant And Equipment Net64.6K87.9K77.2K56.7K929.3K505.7K
Net Debt(2.7M)(12.7M)(16.4M)(1.5M)(8.2M)(7.8M)
Retained Earnings(25.1M)(34.1M)(48.3M)(63.8M)(83.9M)(79.7M)
Accounts Payable3.1M3.5M3.7M2.2M4.9M5.1M
Cash2.8M12.8M16.6M1.5M9.2M9.7M
Non Current Assets Total155.2K137.7K84.5K56.7K929.3K694.6K
Non Currrent Assets Other90.6K49.8K7.3K(56.7K)38.3K36.4K
Cash And Short Term Investments2.8M12.8M16.6M1.5M9.2M9.7M
Net Receivables182.5K111.8K539.1K55.0K122.4K105.2K
Common Stock Shares Outstanding1.1M1.6M6.4M8.4M16.3M17.1M
Liabilities And Stockholders Equity4.1M14.2M19.5M4.2M13.2M13.9M
Non Current Liabilities Total36.1K62.9K18.0K3.5M22.5K21.4K
Inventory242.6K237.9K227.4K254.5K254.4K250.7K
Other Current Assets749.2K854.4K2.1M4.6M2.7M2.8M
Other Stockholder Equity26.0M44.5M64.0M64.5M88.6M93.0M
Total Liab3.2M3.7M3.8M3.5M8.5M8.9M
Total Current Assets4.0M14.1M19.4M4.2M12.3M12.9M
Common Stock12.2K477.0841.0849.02.9K3.7K
Net Tangible Assets936.0K10.5M15.7M734.5K844.7K802.5K
Other Assets129.7K90.6K49.8K7.3K6.6K6.2K
Property Plant Equipment64.6K87.9K77.2K56.7K65.2K56.7K
Net Invested Capital936.0K10.6M15.8M734.5K4.8M5.5M
Property Plant And Equipment Gross64.6K87.9K159.3K158.2K1.1M1.1M
Net Working Capital816.9K10.4M15.6M677.9K3.9M5.2M
Capital Stock12.2K477.0841.0849.02.9K3.5K

Currently Active Assets on Macroaxis

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.